Kulke MH et al. - In a trial to evaluate the efficacy of sunitinib in a 2-cohort study of advanced carcinoid and pancreatic neuroendocrine tumor pts, it was shown that sunitinib has antitumor activity in pancreatic neuroendocrine tumors; its activity against carcinoid tumors could not be definitively determined in this study Methods
Pts were treated with repeated 6-week cycles of oral sunitinib 50 mg/d for 4 weeks, followed by 2 weeks off treatment
Pts were observed for response, survival, and adverse events
Pt-reported outcomes were assessed
Results
Among 109 enrolled pts, 107 received sunitinib
Overall objective response rate (ORR) in pancreatic endocrine tumor pts was 16.7%, and 68% had stable disease (SD)
Among carcinoid pts, ORR was 2.4%, and 83% had SD
Median time to tumor progression was 7.7 months in pancreatic neuroendocrine tumor pts and 10.2 months in carcinoid pts
1-year survival rate was 81.1% in pancreatic neuroendocrine tumor pts and 83.4% in carcinoid pts
No significant differences from baseline in pt-reported quality of life or fatigue were observed during treatment
See all
